The BCL2L11 Knouckout DLD-1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from DLD-1 colorectal adenocarcinoma cells, featuring targeted disruption of the BCL2L11 gene. This heterogeneous pool enables loss-of-function analysis of the encoded BIM protein without clonal selection bias, facilitating studies of intrinsic apoptosis and drug resistance.
DLD-1 is a human colorectal adenocarcinoma cell line with a near-diploid karyotype, extensively used in cancer research to model colorectal tumorigenesis, metastasis, and therapeutic response. Its well-defined genetic background, including mutations in APC and KRAS, provides a relevant context for investigating apoptosis evasion mechanisms.
The BCL2L11 gene encodes BIM (BCL-2-interacting mediator of cell death), a pro-apoptotic BH3-only protein that serves as a master initiator of the intrinsic apoptotic pathway. BIM expression is transcriptionally regulated by FOXO3a and p53, while its pro-apoptotic activity is modulated by phosphorylation via JNK and ERK/MAPK kinases. Following cellular stress or growth factor withdrawal, BIM translocates to the mitochondrial outer membrane and directly neutralizes anti-apoptotic BCL-2 family members, including BCL-2, BCL-XL, and MCL-1. This neutralization liberates the effector proteins BAX and BAK, triggering mitochondrial outer membrane permeabilization and the release of cytochrome c. Subsequently, cytochrome c binds APAF-1, promoting apoptosome assembly and caspase-9 activation, which then cleaves executioner caspases-3 and -7 to execute cell death. BIM additionally interacts with DYNLL1 and HSP70, which regulate its intracellular localization and protein stability.
In colorectal cancer, BIM loss contributes to apoptosis resistance and chemoresistance, making the DLD-1 knockout model highly relevant for dissecting these processes. BCL2L11 disruption in DLD-1 cells mimics tumor-associated defects, allowing researchers to study how colorectal adenocarcinoma cells evade intrinsic apoptosis upon treatment with DNA-damaging agents or BH3 mimetics and to identify compensatory survival mechanisms.
Typical experimental applications for these polyclonal knockout cells include quantitative assessment of apoptosis by Annexin V/PI flow cytometry, immunoblotting for BIM and cleaved caspases-3/9, and cell viability assays following treatment with chemotherapeutics such as 5-fluorouracil or oxaliplatin. The model is also well-suited for co-immunoprecipitation studies of BIM interactions with BCL-2, BCL-XL, or MCL-1, BH3 profiling to measure mitochondrial apoptotic priming, and caspase-3/7 activity assays. Furthermore, it supports drug sensitivity screening for BH3 mimetics and combination therapy strategies that target the BCL-2 regulatory network. For further technical information or to place an inquiry, please contact Ascent Research.
